Evidence map›Paper›PMID 30279194›Full record

ArticleCancer discovery2018

Blood-Based Prediction of Tumor Relapse: The cfDNA Forecast.

Giulia Siravegna, Ryan B Corcoran

Abstract readComment
PubMed Publisher
In one paragraph

Article in Cancer discovery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Giulia SiravegnaCandiolo Cancer Institute-FPO, IRCCS, Candiolo (TO), Italy.
Ryan B CorcoranMassachusetts General Hospital Cancer Center and Department of Medicine, Harvard Medical School, Boston, Massachusetts. rbcorcoran@partners.org.
Candiolo Cancer Institute · ITMassachusetts General Hospital · US

Funding

Tissue and Pathology ResourcesP50CA127003 · NCI · DANA-FARBER CANCER INST · PI BASS, ADAM JOEL · 2007 to 2023
$33.2M
Project 2U54CA224068 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CORCORAN, RYAN BRUCE, FLAHERTY, KEITH T · 2017 to 2021
$6.3M
Therapeutic resistance and tumor heterogeneity in BRAF mutant colorectal cancerR01CA208437 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CORCORAN, RYAN BRUCE · 2016 to 2020
$2.0M
NCI NIH HHS P50 CA127003NCI NIH HHS R01 CA208437NCI NIH HHS U54 CA224068
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Cell-Free Nucleic AcidsColorectal NeoplasmsClonal EvolutionHumansLiquid BiopsyNeoplasm Recurrence, LocalTime-to-TreatmentCell-Free Nucleic Acids

Identifiers

PMID30279194
OpenAlexW2895177076

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.